Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria
Peter Hillmen(Leeds Teaching Hospitals NHS Trust), Neal S. Young(National Institutes of Health), Scott A. Rollins(Alexion Pharmaceuticals (United States)), Petra Muus(Radboud University Nijmegen), Jeff Szer(The Royal Melbourne Hospital), Lucio Luzzatto(Muhimbili University of Health and Allied Sciences), Antonio M. Risitano(Federico II University Hospital), Hubert Schrezenmeier(German Red Cross), Robert A. Brodsky(Johns Hopkins University), Ulrich Dührsen(Essen University Hospital), Leonard Bell, Russell P. Rother(Alexion Pharmaceuticals (United States)), Jörg Schubert(Saarland University), Monica Bessler(Memorial Sloan Kettering Cancer Center), Anita Hill(Leeds General Infirmary), Gèrard Socié(Hôpital Saint-Louis)
Cited by 578
Related Papers
HLA-Haploidentical Bone Marrow Transplantation for Hematologic Malignancies Using Nonmyeloablative Conditioning and High-Dose, Posttransplantation Cyclophosphamide
|Biology of Blood and Marrow Transplantation|2008|1.9k
iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL
|Blood|2018|1.7k
Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2014|1.7k
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
|New England Journal of Medicine|2014|1.6k